Medpace Holdings, Inc. $MEDP Shares Sold by Findlay Park Partners LLP

Findlay Park Partners LLP decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% during the 3rd quarter, Holdings Channel reports. The fund owned 302,300 shares of the company’s stock after selling 5,300 shares during the quarter. Medpace comprises about 1.6% of Findlay Park Partners LLP’s holdings, making the stock its 27th biggest position. Findlay Park Partners LLP’s holdings in Medpace were worth $155,431,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in MEDP. Quent Capital LLC purchased a new position in shares of Medpace during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. purchased a new position in Medpace in the third quarter worth $27,000. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Employees Retirement System of Texas purchased a new stake in shares of Medpace during the 2nd quarter worth $36,000. Finally, Root Financial Partners LLC purchased a new stake in shares of Medpace during the 3rd quarter worth $38,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Medpace news, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total transaction of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Barclays reduced their price objective on shares of Medpace from $525.00 to $500.00 and set an “underweight” rating for the company in a research note on Wednesday, February 11th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and dropped their price objective for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $483.45.

Medpace Price Performance

Shares of MEDP opened at $451.76 on Friday. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92. The stock has a market cap of $12.82 billion, a price-to-earnings ratio of 29.53, a price-to-earnings-growth ratio of 2.14 and a beta of 1.42. The firm has a 50 day simple moving average of $544.42 and a 200-day simple moving average of $538.27.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same quarter in the prior year, the firm earned $3.67 EPS. Medpace’s quarterly revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.